Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of
roniciclib in cancer patients.
To assess safety and tolerability of roniciclib dosing when administered with and without
itraconazole in cancer patients